M7824
GSK buys Merck KGaA’s cancer immunotherapy for $4.2 billion
February 6, 2019Research and Development GSK, M7824, Merck, immunotherapy
British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next …
